CLIENTS TO BENEFIT FROM R&D TAX CREDITS
Marrony has held various business development roles for global life science companies and brings a wealth of knowledge in the areas of microbiology, pharmacology, toxicology, molecular and cellular biology and immunology. She has a Ph.D. in molecular and cellular biology/ immunology from Strasbourg University and was involved in two patents while working at Novartis. She is fluent in French, English and German.
“We are thrilled to have Severine join the Crown team,” said Laurie Heilmann, Senior Vice President of Global Strategy, Marketing and Business Development, Crown Biosciences. “Her business development and technical expertise will support our rapid expansion in France.”
In addition, Crown Bioscience’s application to the French Ministry of National Education, Higher Education and Research (MENESR) to conduct research and development (R&D) for companies in France for the years 2015, 2016 and 2017 has been approved.
The approval has a material impact on Crown Bioscience clients. They will now be able to declare purchased service amounts to be eligible for R&D tax credit (CIR) in accordance with article 244 section B of the general tax code, section 49 F and 49 M of the annex. Crown Bioscience estimates that these tax credits will effectively decrease the net cost of these R&D services by approximately 30 percent.
About Crown Bioscience
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools – Crown Biosciences enables clients to deliver superior clinical candidates.
For more information, please visit www.crownbio.com.